Shi, Y., He, X., Yang, S., Ai, B., Zhang, C., Huang, D., et al. (2007). Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study. Chemotherapy, 53(1), 44-50.

Study Purpose

To compare the efficacy and safety of two different 5-HT₃ receptor antagonists

Intervention Characteristics/Basic Study Process

Patients were randomized to one of two groups. In the first group, patients received ramosetron for prevention of chemotherapy-induced nausea and vomiting (CINV) in cycle 1 of highly emetogenic chemotherapy (HEC) and then ondansetron in cycle 2. Patients in group 2 received ondansetron first, followed by ramosetron.

Sample Characteristics

The study consisted of 50 patients.

Setting

The study was conducted in China.

Study Design

This was a prospective, randomized, crossover trial.

Measurement Instruments/Methods

Nausea, emesis, and loss of appetite were assessed, but the authors did not describe how this data was collected or by whom.

Results

No significance was reported for any measure between groups at any time point.

Conclusions

No significant differences were reported between the two groups on any measure at any time point

Limitations

The sample size was small.
The measures were not clear.